Back to Newsroom

Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial in Pediatrics

GAITHERSBURG, Md., Sept. 29, 2015 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 1 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in healthy children.

Click here to read more